SB 225002CXCR2 antagonist, potent and selective CAS# 182498-32-4 |
- Talnetant
Catalog No.:BCC1981
CAS No.:174636-32-9
- Talnetant hydrochloride
Catalog No.:BCC1982
CAS No.:204519-66-4
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 182498-32-4 | SDF | Download SDF |
PubChem ID | 3854666 | Appearance | Powder |
Formula | C13H10BrN3O4 | M.Wt | 352.14 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | DMSO : ≥ 100 mg/mL (283.98 mM) *"≥" means soluble, but saturation unknown. | ||
Chemical Name | 1-(2-bromophenyl)-3-(2-hydroxy-4-nitrophenyl)urea | ||
SMILES | C1=CC=C(C(=C1)NC(=O)NC2=C(C=C(C=C2)[N+](=O)[O-])O)Br | ||
Standard InChIKey | MQBZVUNNWUIPMK-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C13H10BrN3O4/c14-9-3-1-2-4-10(9)15-13(19)16-11-6-5-8(17(20)21)7-12(11)18/h1-7,18H,(H2,15,16,19) | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Potent and selective CXCR2 chemokine receptor antagonist (IC50 = 22 nM) that displays > 150-fold selectivity over CXCR1 receptors. Causes inhibition of IL-8 and GROα-mediated calcium mobilization in HL60 cells (IC50 values are 8 and 10 nM respectively). Prevents IL-8-induced neutrophil chemotaxis in vitro and sequestration in vivo. Inhibits HIV replication in lymphocytes and macrophages. |
SB 225002 Dilution Calculator
SB 225002 Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.8398 mL | 14.1989 mL | 28.3978 mL | 56.7956 mL | 70.9945 mL |
5 mM | 0.568 mL | 2.8398 mL | 5.6796 mL | 11.3591 mL | 14.1989 mL |
10 mM | 0.284 mL | 1.4199 mL | 2.8398 mL | 5.6796 mL | 7.0994 mL |
50 mM | 0.0568 mL | 0.284 mL | 0.568 mL | 1.1359 mL | 1.4199 mL |
100 mM | 0.0284 mL | 0.142 mL | 0.284 mL | 0.568 mL | 0.7099 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
SB 225002 is a potent and selective CXCR2 chemokine receptor antagonist with IC50 value of 22nM [1].
CXCR2 is a member of the G-protein-coupled receptor family, which is responsible for neutrophil chemotaxis and margination induced by IL-8 [1].
SB 225002 is a potent and selective non-peptide inhibitor of CXCR2. It prevented IL-8 binding to CXCR2 with IC50 value of 22 nM and showed >150-fold selectivity over CXCR1. In HL60 cells, SB 225002 potently prevented IL-8 and GROa-induced neutrophil chemotaxis [1]. In CDDP-resistant and -sensitive OVCA cell lines, SB225002 induced apoptosis in both wild-type and p53-deficient cells in a p53-independent way and promoted mitotic catastrophe [2].
In rabbits, SB 225002 blocked IL-8-induced neutrophil margination [1]. In experimental colitis mice induced by TNBS, SB225002 reduced neutrophil influx, IL-1 , MIP-2, and keratinocyte-derived chemokine (KC) levels, MPO activity and the expression of vascular endothelial growth factor. While, levels of IL-4 and IL-10 were increased significantly in the colons of mice [3].
References:
[1]. White JR, Lee JM, Young PR, et al. Identification of a potent, selective non-peptide CXCR2 antagonist that inhibits interleukin-8-induced neutrophil migration. J Biol Chem, 1998, 273(17): 10095-10098.
[2]. Du M, Qiu Q, Gruslin A, et al. SB225002 promotes mitotic catastrophe in chemo-sensitive and -resistant ovarian cancer cells independent of p53 status in vitro. PLoS One, 2013, 8(1): e54572.
[3]. Manjavachi MN, Quintão NL, Campos MM, et al. The effects of the selective and non-peptide CXCR2 receptor antagonist SB225002 on acute and long-lasting models of nociception in mice. Eur J Pain, 2010, 14(1): 23-31.
- TPMPA
Catalog No.:BCC6903
CAS No.:182485-36-5
- Lomitapide
Catalog No.:BCC5570
CAS No.:182431-12-5
- Rupatadine Fumarate
Catalog No.:BCC4535
CAS No.:182349-12-8
- Baldrinal
Catalog No.:BCN2667
CAS No.:18234-46-3
- Antibiotic 2158
Catalog No.:BCN1825
CAS No.:182320-34-9
- Antibiotic ZG 1494alpha
Catalog No.:BCN1850
CAS No.:182320-33-8
- Synthalin sulfate
Catalog No.:BCC6730
CAS No.:182285-12-7
- Lirioprolioside B
Catalog No.:BCN2740
CAS No.:182284-68-0
- Clausine I
Catalog No.:BCN4687
CAS No.:182261-94-5
- 3,4-seco-Olean-12-en-4-ol-3,28-dioic acid
Catalog No.:BCN7151
CAS No.:182249-69-0
- Nyssoside
Catalog No.:BCN1146
CAS No.:182138-70-1
- Quinovic acid 3-O-(3',4'-O-isopropylidene)-beta-D-fucopyranoside
Catalog No.:BCN1519
CAS No.:182132-59-8
- Thalidezine
Catalog No.:BCN7763
CAS No.:18251-36-0
- (9Z,12Z)-N-Benzyloctadeca-9,12-dienamide
Catalog No.:BCN1518
CAS No.:18286-71-0
- Dibritannilactone B
Catalog No.:BCN7776
CAS No.:1829580-18-8
- Valepotriate
Catalog No.:BCN2351
CAS No.:18296-44-1
- Didrovaltrate
Catalog No.:BCN7124
CAS No.:18296-45-2
- 3,4-O-Isopropylidene shikimic acid
Catalog No.:BCN1147
CAS No.:183075-03-8
- Fabiatrin
Catalog No.:BCN2920
CAS No.:18309-73-4
- Cabazitaxel
Catalog No.:BCC4966
CAS No.:183133-96-2
- Guanylin (human)
Catalog No.:BCC7204
CAS No.:183200-12-6
- Tipiracil hydrochloride
Catalog No.:BCC2001
CAS No.:183204-72-0
- 1,7-Dihydroxy-2,3-methylenedioxyxanthone
Catalog No.:BCN7543
CAS No.:183210-63-1
- AM251
Catalog No.:BCC4412
CAS No.:183232-66-8
Characterization of the molecular interactions of interleukin-8 (CXCL8), growth related oncogen alpha (CXCL1) and a non-peptide antagonist (SB 225002) with the human CXCR2.[Pubmed:12628493]
Biochem Pharmacol. 2003 Mar 1;65(5):813-21.
Neutrophil recruitment to inflammatory sites is mediated by two related receptors: CXC chemokine receptors 1 (CXCR1) and 2 (CXCR2). Both receptors share two ligands, interleukin-8 (CXCL8) and GCP-2 (CXCL6), whereas several chemokines, including growth related oncogen alpha (CXCL1) and a non-peptide antagonist (SB 225002) are specific for CXCR2. The objective of this study was to map the different amino acids involved in the binding and activation/inhibition of human CXCR2. This was performed by exchanging non-conserved amino acids of CXCR2 with their counterparts in CXCR1. The mutants generated showed that: (a) for CXCL8 binding, the N-terminus of CXCR1 and the second extra-cellular loop of CXCR2 are determinant, the N-terminus of CXCR2 is not sufficient and the transmembrane domain seven is probably involved; (b) for CXCL1, the N-terminus of CXCR2 is necessary but not sufficient for binding. The activation study indicated that amino acids critical for activation are not necessarily involved in binding process. Finally, the mechanism of binding of a non-peptide antagonist on CXCR2 was investigated: it occurred through epitopes (a) which were disseminated within the receptor, (b) which differed according to the use of CXCL8 or CXCL1 as a competitor and (c) which did not necessarily overlap with agonist binding sites. We also showed that inhibition of binding and inhibition of activation involved different amino acids.
Interleukin-8 stimulates human immunodeficiency virus type 1 replication and is a potential new target for antiretroviral therapy.[Pubmed:11483765]
J Virol. 2001 Sep;75(17):8195-202.
Production of the C-X-C chemokines interleukin-8 (IL-8) and growth-regulated oncogene alpha (GRO-alpha) in macrophages is stimulated by exposure to human immunodeficiency virus type 1 (HIV-1). We have demonstrated previously that GRO-alpha then stimulates HIV-1 replication in both T lymphocytes and macrophages. Here we demonstrate that IL-8 also stimulates HIV-1 replication in macrophages and T lymphocytes. We further show that increased levels of IL-8 are present in the lymphoid tissue of patients with AIDS. In addition, we demonstrate that compounds which inhibit the actions of IL-8 and GRO-alpha via their receptors, CXCR1 and CXCR2, also inhibit HIV-1 replication in both T lymphocytes and macrophages, indicating potential therapeutic uses for these compounds in HIV-1 infection and AIDS.
Identification of a potent, selective non-peptide CXCR2 antagonist that inhibits interleukin-8-induced neutrophil migration.[Pubmed:9553055]
J Biol Chem. 1998 Apr 24;273(17):10095-8.
Interleukin-8 (IL-8) and closely related Glu-Leu-Arg (ELR) containing CXC chemokines, including growth-related oncogene (GRO)alpha, GRObeta, GROgamma, and epithelial cell-derived neutrophil-activating peptide-78 (ENA-78), are potent neutrophil chemotactic and activating peptides, which are proposed to be major mediators of inflammation. IL-8 activates neutrophils by binding to two distinct seven-transmembrane (7-TMR) G-protein coupled receptors CXCR1 (IL-8RA) and CXCR2 (IL-8RB), while GROalpha, GRObeta, GROgamma, and ENA-78 bind to and activate only CXCR2. A chemical lead, which selectively inhibited CXCR2 was discovered by high throughput screening and chemically optimized. SB 225002 (N-(2-hydroxy-4-nitrophenyl)-N'-(2-bromophenyl)urea) is the first reported potent and selective non-peptide inhibitor of a chemokine receptor. It is an antagonist of 125I-IL-8 binding to CXCR2 with an IC50 = 22 nM. SB 225002 showed >150-fold selectivity over CXCR1 and four other 7-TMRs tested. In vitro, SB 225002 potently inhibited human and rabbit neutrophil chemotaxis induced by both IL-8 and GROalpha. In vivo, SB 225002 selectively blocked IL-8-induced neutrophil margination in rabbits. The present findings suggest that CXCR2 is responsible for neutrophil chemotaxis and margination induced by IL-8. This selective antagonist will be a useful tool compound to define the role of CXCR2 in inflammatory diseases where neutrophils play a major role.